Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US.
Baricitinib
Drug–drug interaction
Janus kinase inhibitors
Real-world study
Rheumatoid arthritis
Tofacitinib
Upadacitinib
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
28
10
2020
accepted:
21
12
2020
pubmed:
24
1
2021
medline:
24
1
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
This study describes the frequency of prescription claims for drugs that may interact with Janus kinase (JAK) inhibitors among adult patients with rheumatoid arthritis (RA) in a large US claims database. This observational, retrospective, cross-sectional study of the IBM A total of 152,853 patients met eligibility criteria. Approximately 76% were women and the median age was 57 years. Of these patients, < 0.1% had a claim for a strong OAT3 inhibitor, and 1% had claims for the combination of a strong CYP3A4 and strong CYP2C19 inhibitor; 3% of patients had a claim for a strong CYP3A4 inhibitor and almost 10% had claims for both a moderate CYP3A4 and a strong CYP2C19 inhibitor. Up to 10% of RA patients have been prescribed a drug with a potential JAK interaction. Rheumatologists should consider potential DDIs when managing patients with RA.
Identifiants
pubmed: 33484433
doi: 10.1007/s40744-020-00275-8
pii: 10.1007/s40744-020-00275-8
pmc: PMC7991043
doi:
Types de publication
Journal Article
Langues
eng
Pagination
599-607Références
Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22:1–12.
doi: 10.2165/00019053-200422001-00002
Treharne GJ, Douglas KM, Iwaszko J, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskelet Care. 2007;5:175–90.
doi: 10.1002/msc.112
Hines LE, Murphy JE, Grizzle AJ, Malone DC. Critical issues associated with drug–drug interactions: highlights of a multistakeholder conference. Am J Health Syst Pharm. 2011;68:941–6.
doi: 10.2146/ajhp100440
Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69:506–17.
doi: 10.1002/art.39953
Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–86.
doi: 10.1056/NEJMoa1310476
Jegatheeswaran J, Turk M, Pope JE. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Immunotherapy. 2019;11:737–54.
doi: 10.2217/imt-2018-0178
Rinvoq [package insert]. North Chicago. AbbVie Inc., IL 2019
Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol. 2016;32:29–33.
doi: 10.1016/j.cbpa.2016.03.006
Olumiant [package insert]. Eli Lilly & Co, Indianapolis 2019
Xeljanz [package insert]. Pfizer Labs, New York 2019
Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–84.
doi: 10.1002/art.38745
Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–82.
doi: 10.1093/nar/gkx1037
van Roon EN, van den Bemt PM, Jansen TL, et al. An evidence-based assessment of the clinical significance of drug–drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. Clin Ther. 2009;31:1737–46.
doi: 10.1016/j.clinthera.2009.08.009
Ko Y, Malone DC, Skrepnek GH, et al. Prescribers’ knowledge of and sources of information for potential drug–drug interactions: a postal survey of US prescribers. Drug Saf. 2008;31:525–36.
doi: 10.2165/00002018-200831060-00007
Kern DM, Chang L, Sonawane K, et al. Treatment patterns of newly diagnosed rheumatoid arthritis patients from a commercially insured population. Rheumatol Ther. 2018;5:355–69.
doi: 10.1007/s40744-018-0114-6